BioSpace News Archive

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021

IsoPlexis, a leader in functional single-cell proteomics, today announced the appointment of Dr. Jason Myers to its Board of Directors.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that members of its leadership team will participate in the Next-Gen Cytokine Therapeutics Summit today.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2021 Cantor Virtual Global Healthcare Conference.

Blue Water Vaccines, Inc. a biopharmaceutical company developing vaccines, announced that it has exclusive rights to a United States patent recently awarded to its licensor, Oxford University Innovation Limited.

Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial and viral metalloenzymes, announced today that it has been awarded further support from CARB-X of an additional $1.36M in option funding to advance the development of its FG-LpxC LUNG antibiotic program to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa

Boundless Bio today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.

CARISMA Therapeutics Inc. announced today that that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CT-0508

CG Oncology, Inc. announced today that it has entered into a clinical trial collaboration agreement to evaluate the combination of CG Oncology’s investigational oncolytic immunotherapy CG0070, with Roche’s atezolizumab, an anti-PD-L1 (programmed death-ligand 1) therapy.

Ferring Pharmaceuticals and Rebiotix today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides difficile (C. difficile) infection, as part of IDWeek 2021.